NIKKEI 225
38,946.93 -122.75 (-0.31%) HANG SENG
19,220.62 -415.60 (-2.12%) CRUDE OIL
78.88 -0.92 (-1.15%) GOLD FUTURES
2,425.20 -13.30 (-0.55%) DOW
39,815.96 +9.19 (+0.02%) Bitcoin GBP
54,865.32 +1,193.33 (+2.22%)
ORGS May 2024 2.500 put
| Previous close | 1.6100 |
| Open | 1.6100 |
| Bid | 1.5500 |
| Ask | 2.3000 |
| Strike | 2.50 |
| Expiry date | 2024-05-17 |
| Day's range | 1.6100 - 1.6100 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
GlobeNewswireOrgenesis Provides Business Update for the First Quarter of 2024
Accelerates rollout of POCare platform following partnership agreement with Germfree and acquisition regaining full ownership and control over OctomeraGERMANTOWN, Md., May 21, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today provided a business update for the first quarter ended March 31, 2024. Vered Capl
- GlobeNewswire
Orgenesis Provides Year End Business Update
Major transformation underway commencing with recent acquisitionreasserting full ownership and control over Octomera Secured a $2.3 million investment from a group including sophisticated healthcare professionals at $1.03 per share and accompanying warrants, a more than 50% premium to prior-day closing price Entered into asset purchase and strategic collaboration agreement which will provide Octomera with over $8 million of initial collaboration payments GERMANTOWN, Md., April 15, 2024 (GLOBE NE
- GlobeNewswire
Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility
ORMOND BEACH, Fla. and GERMANTOWN, Md., April 10, 2024 (GLOBE NEWSWIRE) -- Germfree, a leading innovator in modular cleanroom infrastructure and services, and Orgenesis Inc. (Nasdaq: ORGS), a global leader in decentralizing cell and gene therapies (CGTs), today announced an asset purchase and strategic partnership aimed at advancing Orgenesis’ therapeutic programs and its suite of product development and GMP cell processing services. The collaboration’s goal is to transform the production of cel
